NASDAQ:DOX

Amdocs Stock Forecast, Price & News

$58.32

+0.33 (+0.57 %)

(As of 09/21/2020 12:00 AM ET)

Add

Compare

Today's Range

$57.10

Now: $58.32▼

$58.32

50-Day Range

$57.04

MA: $60.14▼

$62.66

52-Week Range

$44.05

Now: $58.32▼

$77.29

Volume693,472 shs

Average Volume914,161 shs

Market Capitalization$7.86 billion

P/E Ratio16.25

Dividend Yield2.26%

Beta0.65

Amdocs Limited, through its subsidiaries, provides software and services to the communications, pay TV, entertainment, and media industry service providers worldwide. The company offers amdocsONE a line of services designed for various stages of a service provider's lifecycle, including planning, delivery, implementation, and ongoing support, as well as consumer experience and monetization, media and digital, enterprise and connected society, service-driven network, and services and agile operation solutions. It also provides managed, quality engineering, data and intelligence, cloud enablement, digital business operation, autonomous network service assurance, and advisory services. In addition, the company offers mobile financial services, which enable service providers and financial institutions to serve financially underserved customer segments; revenue guard services designed to detect and resolve revenue leakage, fraud, and cyber fraud; and the BriteBill, a multi-channel bill presentment platform focused on contextual and personalized customer engagements. Further, it provides advertising and media services for media publishers, TV networks, video streaming providers, advertising agencies, and service providers. The company was founded in 1988 and is headquartered in Chesterfield, Missouri.

Beat the Market (BTM) Rank^™

3.3 Analyst's Opinion

Consensus Rating
Amdocs has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $74.40, Amdocs has a forecasted upside of 27.6% from its current price of $58.32.
Amount of Analyst Coverage
Amdocs has only been the subject of 1 research reports in the past 90 days.

2.9 Community Rank

Outperform Votes
Amdocs has received 624 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Amdocs has received 466 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Amdocs has received 57.25% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Amdocs and other stocks. Vote “Outperform” if you believe DOX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DOX will underperform the S&P 500 over the long term. You may vote once every thirty days.

3.3 Dividend Strength

Dividend Yield
Amdocs pays a meaningful dividend of 2.26%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Amdocs has been increasing its dividend for 6 years.
Dividend Coverage
The dividend payout ratio of Amdocs is 32.19%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Amdocs will have a dividend payout ratio of 29.84% next year. This indicates that Amdocs will be able to sustain or increase its dividend.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Amdocs insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 15.40% of the stock of Amdocs is held by insiders.
Percentage Held by Institutions
91.23% of the stock of Amdocs is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9 Earnings and Valuation

Earnings Growth
Earnings for Amdocs are expected to grow by 6.30% in the coming year, from $4.13 to $4.39 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Amdocs is 16.25, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 18.37.
Price to Earnings Ratio vs. Sector
The P/E ratio of Amdocs is 16.25, which means that it is trading at a less expensive P/E ratio than the Computer and Technology sector average P/E ratio of about 61.65.
Price to Earnings Growth Ratio
Amdocs has a PEG Ratio of 1.65. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Amdocs has a P/B Ratio of 2.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

2.48 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Custom computer programming services

Sub-IndustryIT Consulting & Other Services

SectorComputer and Technology

Current SymbolNASDAQ:DOX

Previous Symbol

CUSIPG0260210

CIK1062579

Webwww.amdocs.com

Phone1 314 212 7000

Debt

Debt-to-Equity Ratio0.24

Current Ratio1.84

Quick Ratio1.84

Price-To-Earnings

Trailing P/E Ratio16.25

Forward P/E Ratio14.12

P/E Growth1.65

Sales & Book Value

Annual Sales$4.09 billion

Price / Sales1.92

Cash Flow$5.73 per share

Price / Cash Flow10.17

Book Value$26.28 per share

Price / Book2.22

Profitability

EPS (Most Recent Fiscal Year)$4.07

Net Income$479.45 million

Net Margins11.71%

Return on Equity15.30%

Return on Assets9.57%

Miscellaneous

Employees24,516

Outstanding Shares134,773,000

Market Cap$7.86 billion

Next Earnings Date11/10/2020 (Estimated)

OptionableOptionable

$58.32

+0.33 (+0.57 %)

(As of 09/21/2020 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive DOX News and Ratings via Email

Sign-up to receive the latest news and ratings for DOX and its competitors with MarketBeat's FREE daily newsletter.

Amdocs (NASDAQ:DOX) Frequently Asked Questions

How has Amdocs' stock price been impacted by COVID-19 (Coronavirus)?

Amdocs' stock was trading at $61.42 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, DOX shares have decreased by 5.0% and is now trading at $58.32.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Amdocs?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amdocs in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Amdocs.

When is Amdocs' next earnings date?

Amdocs is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Amdocs.

How were Amdocs' earnings last quarter?

Amdocs Limited (NASDAQ:DOX) issued its earnings results on Wednesday, August, 5th. The technology company reported $1.07 EPS for the quarter, beating the Zacks' consensus estimate of $1.05 by $0.02. The technology company earned $1.03 billion during the quarter, compared to analyst estimates of $1.01 billion. Amdocs had a return on equity of 15.30% and a net margin of 11.71%.
View Amdocs' earnings history.

How often does Amdocs pay dividends? What is the dividend yield for Amdocs?

Amdocs declared a quarterly dividend on Wednesday, August 5th. Stockholders of record on Wednesday, September 30th will be given a dividend of $0.327 per share on Friday, October 23rd. This represents a $1.31 annualized dividend and a dividend yield of 2.24%. The ex-dividend date is Tuesday, September 29th.
View Amdocs' dividend history.

What guidance has Amdocs issued on next quarter's earnings?

Amdocs issued an update on its fourth quarter earnings guidance on Wednesday, August, 5th. The company provided EPS guidance of $1.16-1.22 for the period, compared to the Thomson Reuters consensus estimate of $1.16. The company issued revenue guidance of $1.015-1.055 billion, compared to the consensus revenue estimate of $1.03 billion.

What price target have analysts set for DOX?

5 analysts have issued 12 month price objectives for Amdocs' stock. Their forecasts range from $72.00 to $76.00. On average, they expect Amdocs' stock price to reach $74.40 in the next year. This suggests a possible upside of 27.6% from the stock's current price.
View analysts' price targets for Amdocs.

Who are some of Amdocs' key competitors?

Some companies that are related to Amdocs include Accenture (ACN), IBM (IBM), Cognizant Technology Solutions (CTSH), EPAM Systems (EPAM), Leidos (LDOS), Booz Allen Hamilton (BAH), Gartner (IT), Caci International (CACI), Mantech International (MANT), Teradata (TDC), Virtusa (VRTU), Unisys (UIS), Forrester Research (FORR), The Hackett Group (HCKT) and Servicesource International (SREV).
View all competitors.

What other stocks do shareholders of Amdocs own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amdocs investors own include AT&T (T), Pfizer (PFE), Home Depot (HD), Exxon Mobil (XOM), AbbVie (ABBV), IBM (IBM), NVIDIA (NVDA), Comcast (CMCSA), Cisco Systems (CSCO) and Walt Disney (DIS).

Who are Amdocs' key executives?

Amdocs' management team includes the following people:

Mr. Joshua Sheffer, Pres & CEO (Age 59)
Ms. Tamar Rapaport-Dagim, CFO & COO (Age 48)
Mr. Matthew E. Smith, Sec. & Head of Investor Relations (Age 47)
Mr. Gary Miles, Chief Marketing Officer
Darcy Antonellis, Head of Amdocs Media

What is Amdocs' stock symbol?

Amdocs trades on the NASDAQ under the ticker symbol "DOX."

Who are Amdocs' major shareholders?

Amdocs' stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (11.52%), Nordea Investment Management AB (5.12%), LSV Asset Management (3.80%), AQR Capital Management LLC (1.63%), Robeco Institutional Asset Management B.V. (1.32%) and Bank of America Corp DE (1.29%).

Which major investors are selling Amdocs stock?

DOX stock was sold by a variety of institutional investors in the last quarter, including Cooke & Bieler LP, AQR Capital Management LLC, FIL Ltd, Goldman Sachs Group Inc., Anchor Capital Advisors LLC, Two Sigma Advisers LP, Nuveen Asset Management LLC, and Charles Schwab Investment Management Inc..

Which major investors are buying Amdocs stock?

DOX stock was acquired by a variety of institutional investors in the last quarter, including Nordea Investment Management AB, FMR LLC, LSV Asset Management, Wedge Capital Management L L P NC, Alyeska Investment Group L.P., Prudential Financial Inc., CWM LLC, and Principal Financial Group Inc..

How do I buy shares of Amdocs?

Shares of DOX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amdocs' stock price today?

One share of DOX stock can currently be purchased for approximately $58.32.

How big of a company is Amdocs?

Amdocs has a market capitalization of $7.86 billion and generates $4.09 billion in revenue each year. The technology company earns $479.45 million in net income (profit) each year or $4.07 on an earnings per share basis. Amdocs employs 24,516 workers across the globe.

What is Amdocs' official website?

The official website for Amdocs is www.amdocs.com.

How can I contact Amdocs?

Amdocs' mailing address is 1390 Timberlake Manor Parkway, Chesterfield MO, 63017. The technology company can be reached via phone at 1 314 212 7000 or via email at [email protected]

This page was last updated on 9/21/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings